Cargando…

Monthly migraine days, tablet utilization, and quality of life associated with Rimegepant – post hoc results from an open label safety study (BHV3000–201)

BACKGROUND: The objective of this study was to describe patterns in monthly migraine days (MMD) and tablet utilization, and to estimate health-related quality of life (HRQoL) measures in patients treated as needed (PRN) with rimegepant 75 mg over 52-weeks. METHODS: Eligible subjects were adults with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Johnston, Karissa, Harris, Linda, Powell, Lauren, Popoff, Evan, Coric, Vladimir, L’Italien, Gilbert, Schreiber, Curtis P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Milan 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8903552/ https://www.ncbi.nlm.nih.gov/pubmed/35038983 http://dx.doi.org/10.1186/s10194-021-01378-5

Ejemplares similares

Health State Utility Mapping of Rimegepant for the Preventive Treatment of Migraine: Double-Blind Treatment Phase and Open Label Extension (BHV3000-305)
por: Powell, Lauren C., et al.
Publicado: (2022)

Rimegepant, Ubrogepant, and Lasmiditan in the Acute Treatment of Migraine Examining the Benefit-Risk Profile Using Number Needed to Treat/Harm
por: Johnston, Karissa M, et al.
Publicado: (2022)

Mapping Migraine-Specific Quality of Life to Health State Utilities in Patients Receiving Rimegepant
por: Johnston, Karissa M., et al.
Publicado: (2021)

Matching‐adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health‐related quality of life in the treatment of migraine
por: Popoff, Evan, et al.
Publicado: (2021)

Is the right way to go in between?: Rimegepant as needed provides preventive benefit. A comment on: monthly migraine days, tablet utilization, and quality of life associated with rimegepant—post hoc results from an open label safety study (BHV3000–201)
por: Gantenbein, Andreas R., et al.
Publicado: (2023)

Measuring interictal burden among people affected by migraine: a descriptive survey study
por: Hubig, Lena T., et al.
Publicado: (2022)

A stated preference survey to explore patient preferences for novel preventive migraine treatments
por: Hubig, Lena T., et al.
Publicado: (2022)

Real-World experience of interictal burden and treatment in migraine: a qualitative interview study
por: Lo, Siu Hing, et al.
Publicado: (2022)

Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine
por: Berman, Gary, et al.
Publicado: (2020)

ICER’s assessment of lasmiditan, rimegepant, and ubrogepant for acute migraine
por: Franklin, Meg, et al.
Publicado: (2020)

The burden of medication overuse headache and patterns of switching and discontinuation among triptan users: a systematic literature review
por: Deighton, Alison M., et al.
Publicado: (2021)

Real‐world assessment of the relationship between migraine‐related disability and healthcare costs in the United States
por: Harris, Linda, et al.
Publicado: (2022)

Rimegepant: A Review in the Acute Treatment and Preventive Treatment of Migraine
por: Blair, Hannah A.
Publicado: (2023)

Observational Analysis of the Costs Associated with Acute Treatment of Breakthrough Migraine Attacks in Medicaid Patients Using Preventive Therapies
por: Harris, Linda, et al.
Publicado: (2023)

Correction to: Rimegepant: A Review in the Acute Treatment and Preventive Treatment of Migraine
por: Blair, Hannah A.
Publicado: (2023)

Epidemiology and genetic characterization of BVDV, BHV-1, BHV-4, BHV-5 and Brucella spp. infections in cattle in Turkey
por: ASLAN, Muhammet Eren, et al.
Publicado: (2015)

Efficacy and Safety of Rimegepant for the Acute Treatment of Migraine: Evidence From Randomized Controlled Trials
por: Gao, Bixi, et al.
Publicado: (2020)

Clinical efficacy and safety of rimegepant in the treatment of migraine: a meta-analysis of randomized controlled trials
por: Wang, Qinghui, et al.
Publicado: (2023)

Assessing Effects of BHV-0223 40 mg Zydis Sublingual Formulation and Riluzole 50 mg Oral Tablet on Liver Function Test Parameters Utilizing DILIsym
por: Longo, Diane M, et al.
Publicado: (2020)

A Framework for Estimating the Eligible Patient Population for New Migraine Acute Therapies in the United States
por: Harris, Linda, et al.
Publicado: (2021)

Relative efficacy of lasmiditan versus rimegepant and ubrogepant as acute treatments for migraine: network meta-analysis findings
por: Polavieja, Pepa, et al.
Publicado: (2022)

Antagonism of CGRP Signaling by Rimegepant at Two Receptors
por: Pan, Kylie S., et al.
Publicado: (2020)

Human Milk and Plasma Pharmacokinetics of Single-Dose Rimegepant 75 mg in Healthy Lactating Women
por: Baker, Teresa E., et al.
Publicado: (2022)

P‐Glycoprotein and Breast Cancer Resistance Protein Transporter Inhibition by Cyclosporine and Quinidine on the Pharmacokinetics of Oral Rimegepant in Healthy Subjects
por: Bhardwaj, Rajinder, et al.
Publicado: (2022)

BHV1 infections: Relevance and spread in Europe
por: Straub, Otto Christian
Publicado: (1991)

Incidence and cost of treatment-emergent comorbid events in insured patients with chronic hepatitis C virus infection: a retrospective cohort study
por: Sapra, Sandhya, et al.
Publicado: (2014)

Use of Rimegepant in the Management of Cervicogenic Headache Secondary to Trauma: A Case Series
por: Zaw, Shin T, et al.
Publicado: (2023)

BVDV and BHV-1 Infections in Dairy Herds in Northern and Northeastern Thailand
por: Kampa, J, et al.
Publicado: (2004)

The Antiapoptotic Effect of BHV-1 in Sorbitol-induced Apoptosis in MDBK Cells
por: Marfè, G., et al.
Publicado: (2001)

Impact of early intervention and disease modification in patients with predementia Alzheimer’s disease: a Markov model simulation
por: Budd, David, et al.
Publicado: (2011)

Measurement properties of the Flu-Like Symptom Index from the Hepatitis Physical Symptom Severity Diary
por: Mathias, Susan, et al.
Publicado: (2013)

Review of patient-reported outcome measures in chronic hepatitis C
por: Kleinman, Leah, et al.
Publicado: (2012)

BHV-1 induced oxidative stress contributes to mitochondrial dysfunction in MDBK cells
por: Zhu, Liqian, et al.
Publicado: (2016)

Immunization of cattle with recombinant Newcastle disease virus expressing bovine herpesvirus-1 (BHV-1) glycoprotein D induces mucosal and serum antibody responses and provides partial protection against BHV-1
por: Khattar, Sunil K., et al.
Publicado: (2010)

A phase Ib dose-escalation study of troriluzole (BHV-4157), an oral glutamatergic signaling modulator, in combination with nivolumab in patients with advanced solid tumors
por: Silk, Ann W., et al.
Publicado: (2022)

The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913)
por: Hanssens, Linda, et al.
Publicado: (2008)

Impact of Refractory Myasthenia Gravis on Health-Related Quality of Life
por: Boscoe, Audra N., et al.
Publicado: (2019)

Economic Impact of Early-in-Hospital Diagnosis and Initiation of Eculizumab in Atypical Haemolytic Uraemic Syndrome
por: Ryan, Michael, et al.
Publicado: (2019)

The temporal trend of placebo response in migraine prevention from 1990 to 2021: a systematic literature review and meta-analysis with regression
por: Tepper, Stewart J., et al.
Publicado: (2023)

Induction of humoral responses to BHV-1 glycoprotein D expressed by HSV-1 amplicon vectors
por: Blanc, Andrea Maria, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_ccgvq5v3lc337f13985edj3lgm